DDInter1677 DDInter1628
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) downregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Cabazitaxel {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Triamcinolone {u} (Compound) upregulates {v} (Gene) PRKAG2
PRKAG2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Ruxolitinib (Compound)
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) upregulates PRKAG2 (Gene) and PRKAG2 (Gene) is downregulated by Ruxolitinib (Compound)